During the past decade, Azienda Ospedaliera Bianchi Melacrino Morelli conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 17 clinical trials were completed, i.e. on average, 44.7% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 15 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Bianchi Melacrino Morelli" #1 sponsor was "Celgene" with 12 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 12 trials sponsored, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 6 trials sponsored, "Incyte Corporation" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Bianchi Melacrino Morelli" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 5 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator and "Annunziata Hospital, Cosenza, Italy" with 1 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Bianchi Melacrino Morelli" are "Myelodysplastic Syndromes" (8 trials), "Leukemia" (4 trials), "Multiple Myeloma" (4 trials), "Myelofibrosis" (4 trials) and "Critical Illness" (3 trials). Many other conditions were trialed in "Azienda Ospedaliera Bianchi Melacrino Morelli" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Bianchi Melacrino Morelli" are "Drug" (60 trials), "Other" (13 trials), "Procedure" (6 trials), "Device" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Azacitidine" (5 trials), "Lenalidomide" (5 trials), "Rituximab" (5 trials) and "Prednisone" (4 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Bianchi Melacrino Morelli" are 75 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Bianchi Melacrino Morelli". 1 are not yet recruiting, 12 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Azienda Ospedaliera Bianchi Melacrino Morelli, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Bianchi Melacrino Morelli, 2 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Azienda Ospedaliera Bianchi Melacrino Morelli has several departments that took part in Clinical trials: "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia" - 7 trials, "Ao Bianchi Melacrino Morelli- Po Riuniti - Divisione Di Cardiologia" - 4 trials, "Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"" - 31 trials